LGD-4033 (Ligandrol): A Complete SARM Guide

LGD-4033, commonly known as Ligandrol, is one of the more thoroughly documented selective androgen receptor modulators in the published literature. Originally developed by Ligand Pharmaceuticals and later advanced by Viking Therapeutics as VK5211, it occupies an unusual position in the SARM landscape: a non-steroidal compound with completed phase-1 human safety data, ongoing phase-2 trials for specific indications, and a binding profile that has been characterized in multiple peer-reviewed publications.

Chemistry and receptor binding

LGD-4033 is a non-steroidal, orally bioavailable small molecule. Unlike anabolic-androgenic steroids, which share the four-ring cyclopentanoperhydrophenanthrene backbone of testosterone, Ligandrol is structurally unrelated to steroid hormones. It belongs to a chemical class sometimes described as aryl-propionamide-derived, though its scaffold has been refined away from the earlier aryl-propionamide SARMs such as S-4 (Andarine).

In in-vitro binding assays, LGD-4033 has been reported to bind the androgen receptor with high affinity — values in the low nanomolar range are cited across the published literature. The characteristic that distinguishes SARMs from exogenous testosterone is tissue selectivity: preferential agonism at the androgen receptor in skeletal muscle and bone, with reduced activity in prostate tissue, sebaceous glands, and the scalp. In rodent models, LGD-4033 has been reported to produce dose-dependent increases in lean mass and bone mineral density at doses far below those required to stimulate prostate weight gain. Researchers interpret this dissociation as evidence of a favorable therapeutic index, though the mechanism behind tissue selectivity — likely involving differential co-activator recruitment at the androgen receptor — is not fully resolved.

Among widely discussed SARMs, LGD-4033 is often described as among the most selective, though direct head-to-head selectivity comparisons in humans are sparse. Most selectivity claims rest on preclinical rodent data and extrapolation from binding studies.

Published human trials

LGD-4033 is unusual among SARMs in that it has undergone formal phase-1 clinical evaluation in healthy human volunteers. The most frequently cited trial was conducted by researchers at Boston University and published by Basaria et al. in 2013 in The Journals of Gerontology. In this randomized, double-blind, placebo-controlled study, 76 healthy men aged 21–50 received placebo or LGD-4033 at 0.1, 0.3, or 1.0 mg daily for 21 days.

Reported findings from that trial included:

• Dose-dependent increases in lean body mass over the three-week dosing period.
• Suppression of total testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, and triglycerides.
• A return of hormonal markers toward baseline during the follow-up period after dosing ended.
• No serious adverse events reported at the doses studied.

The trial used doses considerably lower than the 5–10 mg range commonly discussed in non-clinical contexts. This gap between studied doses and commonly reported research doses is an important caveat when interpreting safety.

Subsequent human work has focused on specific clinical indications. Viking Therapeutics has investigated VK5211 in patients recovering from hip fracture, with phase-2 results reported in 2018 showing increases in lean body mass relative to placebo. Additional trials have explored applications in muscle-wasting conditions, cancer cachexia, and age-related sarcopenia, though as of this writing no SARM — including Ligandrol — has received regulatory approval for any indication in the United States, Canada, or the European Union.

Dosing theory in research contexts

In non-clinical research discussions, LGD-4033 is typically referenced at 5–10 mg once daily, taken orally. The compound has a reported elimination half-life of approximately 24–36 hours in humans, which supports once-daily dosing without significant trough variation. Because it is not hepatically 17-alpha-alkylated (as many oral anabolic steroids are), split dosing for pharmacokinetic reasons is generally considered unnecessary.

Research cycles described in the literature and in survey data of non-clinical users commonly span 8 weeks, occasionally extended to 12. The rationale for the 8-week window is pragmatic rather than evidence-based: it balances the time required to observe measurable changes in body composition against the accumulating degree of hypothalamic-pituitary-gonadal axis suppression.

Several dosing considerations appear consistently across the published and grey literature:

• Response is reported to scale with dose, but so does suppression. The Basaria 2013 data showed clear suppression at 1.0 mg daily, well below commonly referenced research doses.
• Food does not appear to meaningfully alter absorption; oral bioavailability is reported as high.
• Stacking with other SARMs or anabolics compounds both the anabolic signal and the suppressive effect, and published human data on combinations are essentially nonexistent.

It should be emphasized that 5–10 mg is a convention derived from community practice, not from regulatory-grade dose-finding studies.

Suppression and recovery

LGD-4033 suppresses endogenous testosterone production in a dose-dependent manner. This is consistently reported across the Basaria trial, Viking's phase-2 data, and anecdotal bloodwork shared in non-clinical research circles. Suppression is generally characterized as moderate — less severe than a full-dose exogenous testosterone cycle, but meaningful enough that recovery is not always spontaneous after short cycles, and is unreliable after longer ones.

Markers typically affected include:

• Total and free testosterone, often reduced into hypogonadal ranges during dosing.
• Luteinizing hormone and follicle-stimulating hormone, both suppressed via negative feedback at the hypothalamus and pituitary.
• Sex hormone-binding globulin, consistently reduced.
• HDL cholesterol, reduced in a dose-dependent manner.

In the Basaria 2013 trial, hormone markers trended back toward baseline within roughly 5 weeks after cessation at the low doses studied. At the higher doses commonly discussed in research contexts, recovery timelines reported in community bloodwork are longer and more variable.

Post-cycle therapy protocols discussed in non-clinical literature typically involve a selective estrogen receptor modulator such as Tamoxifen (Nolvadex) for 4 weeks following cessation, with the theoretical mechanism being blockade of estrogenic negative feedback at the hypothalamus to accelerate recovery of LH and FSH secretion. The clinical evidence base for SERM-driven PCT specifically following SARM use is limited; most of the supporting evidence is extrapolated from studies in men with secondary hypogonadism from other causes.

Baseline bloodwork before any research protocol, and follow-up bloodwork during and after, is standard practice in rigorous research settings. Minimum panels typically include total and free testosterone, LH, FSH, estradiol, SHBG, a full lipid panel, and liver enzymes.

Hepatotoxicity and other safety considerations

One of the frequently cited advantages of SARMs over oral anabolic-androgenic steroids is reduced first-pass hepatic stress. LGD-4033 is not 17-alpha-alkylated and does not require the structural modification that drives much of the hepatotoxicity associated with oral steroids such as oxandrolone or stanozolol.

That said, hepatotoxicity has been reported in human case reports involving non-clinical SARM use. A 2020 case series in the Journal of Clinical and Translational Hepatology described drug-induced liver injury in users of products sold as LGD-4033 and other SARMs, typically presenting as cholestatic or mixed-pattern hepatitis weeks into use. A significant complicating factor in these reports is product purity: analytical testing of SARM-labeled products sold outside of pharmaceutical channels has repeatedly found mislabeled contents, unlabeled active compounds, and contamination.

Other reported adverse effects include:

• Transient elevations in liver enzymes, often reversing after cessation.
• Reductions in HDL cholesterol sufficient to warrant monitoring in longer protocols.
• Mild water retention and subjective reports of fatigue, particularly in the first week.
• Headache, reported in a minority of users across both clinical and non-clinical contexts.

Cardiovascular risk is not fully characterized. The consistent HDL suppression seen across studies is a signal worth taking seriously in any prolonged use, though the magnitude of long-term cardiovascular impact in research contexts remains unquantified.

Position relative to other SARMs

Within the SARM category, LGD-4033 is most often compared with RAD-140 (Testolone), the two occupying the "strength and mass" end of the SARM spectrum alongside milder compounds such as Ostarine (MK-2866) and more specialized agents such as Andarine (S-4) and YK-11.

Relative to RAD-140, Ligandrol is typically described as:

• Producing leaner, less dramatic strength gains — more analogous in subjective reports to a mild testosterone base than to a harsh compound.
• Associated with somewhat less aggressive suppression at equivalent subjective dose strength, though both compounds meaningfully suppress the HPG axis.
• Better characterized in human pharmacokinetic and phase-1 safety data, owing to the Basaria trial and Viking's clinical program.
• Less associated with subjective reports of aggression, sleep disruption, or neurological side effects than RAD-140, though controlled comparative data are not available.

Relative to Ostarine, LGD-4033 is reported to be meaningfully more suppressive and to produce larger changes in lean mass per week of dosing. Ostarine occupies the entry point of the SARM category; Ligandrol sits a clear step above it in both reported effect and reported impact on endogenous hormonal output.

None of these comparative descriptions rest on controlled head-to-head human trials. They reflect a combination of binding data, rodent pharmacology, and the aggregated self-reported experience documented in non-clinical research contexts — a literature that should be treated with appropriate skepticism.

Open questions

Several aspects of Ligandrol's profile remain under-characterized despite its being among the most-studied SARMs.

Long-term safety at research-relevant doses is the most obvious gap. The Basaria trial used 0.1–1.0 mg for 21 days; commonly referenced research doses are 5–10× higher and 4× longer in duration. Extrapolating safety across that gap is not defensible on the published data alone.

The mechanism of tissue selectivity, while theorized to involve differential co-activator recruitment and tissue-specific androgen receptor conformations, is not resolved at the molecular level. Whether the selectivity observed in rodent tissues translates fully to humans — particularly in prostate and sebaceous tissue over longer dosing windows — remains an open question.

Recovery dynamics after longer, higher-dose protocols are poorly documented in controlled settings. Most of the recovery data available comes from non-clinical bloodwork shared in research communities, which is neither systematic nor verifiable.

Finally, product identity outside of pharmaceutical channels is a persistent issue. Researchers working with SARM-labeled compounds should assume that independent analytical verification of identity and purity is a prerequisite to interpreting any result obtained with them.